FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008629622> ?p ?o ?g. }

• W3008629622 endingPage "359" @default.
• W3008629622 startingPage "353" @default.
• W3008629622 abstract "Purpose Radiation therapy (RT), a standard breast cancer (BC) treatment modality, is associated with a small increased risk of in-field second primary malignancy (SPM). SPM rates after RT in BRCA mutation carriers have rarely been reported. An elevated risk of SPM would affect the safety of breast conservation for early BC or prophylactic radiation as a method of prevention. We analyzed a population of BRCA carriers irradiated for BC to determine whether there is an elevated rate of SPM. Methods and Materials Patients with BC who were BRCA1 or BRCA2 carriers and were treated with breast and/or chest wall RT with or without regional lymph nodes between 1991 and 2012 at a single institution were retrospectively identified. Only those with ≥5 years of follow-up with adequate demographic, tumor, and radiation data were included. SPMs were recorded, and previously delivered RT doses to the organ and site of malignancy were determined. Results Two hundred thirty women, of whom 80% carried an Ashkenazi Jewish founder mutation, met entry criteria with 3-dimensional RT delivered to 266 breasts or chest walls, including regional nodes in 110 (41%). With a median follow-up of 10 years (range, 5-27; mean 11.4) comprising 3042 person-years, 6 SPMs developed, of which only 1 (papillary thyroid carcinoma) was within the radiation field (crude rate of 0.38% of irradiated breasts or chest walls), diagnosed 17 years after RT. This corresponds to an incidence of 0.32 per 1000 woman-years. The Kaplan–Meier estimate of 20-year freedom from a radiation-induced SPM is 99.5%. Calculated dose exposure to the out-of-field SPMs ranged from 0.1 to 1 Gy. No patient developed an in-field skin cancer or sarcoma. Conclusions In this largest cohort of women treated with radiation therapy for BRCA-associated breast cancer, we identified no signal for an increased risk of radiation-induced SPMs compared with the general BC population, and the risk is extraordinarily small. Although larger cohorts and longer follow-up are needed, these results support the safety of RT in BRCA carriers. Radiation therapy (RT), a standard breast cancer (BC) treatment modality, is associated with a small increased risk of in-field second primary malignancy (SPM). SPM rates after RT in BRCA mutation carriers have rarely been reported. An elevated risk of SPM would affect the safety of breast conservation for early BC or prophylactic radiation as a method of prevention. We analyzed a population of BRCA carriers irradiated for BC to determine whether there is an elevated rate of SPM. Patients with BC who were BRCA1 or BRCA2 carriers and were treated with breast and/or chest wall RT with or without regional lymph nodes between 1991 and 2012 at a single institution were retrospectively identified. Only those with ≥5 years of follow-up with adequate demographic, tumor, and radiation data were included. SPMs were recorded, and previously delivered RT doses to the organ and site of malignancy were determined. Two hundred thirty women, of whom 80% carried an Ashkenazi Jewish founder mutation, met entry criteria with 3-dimensional RT delivered to 266 breasts or chest walls, including regional nodes in 110 (41%). With a median follow-up of 10 years (range, 5-27; mean 11.4) comprising 3042 person-years, 6 SPMs developed, of which only 1 (papillary thyroid carcinoma) was within the radiation field (crude rate of 0.38% of irradiated breasts or chest walls), diagnosed 17 years after RT. This corresponds to an incidence of 0.32 per 1000 woman-years. The Kaplan–Meier estimate of 20-year freedom from a radiation-induced SPM is 99.5%. Calculated dose exposure to the out-of-field SPMs ranged from 0.1 to 1 Gy. No patient developed an in-field skin cancer or sarcoma. In this largest cohort of women treated with radiation therapy for BRCA-associated breast cancer, we identified no signal for an increased risk of radiation-induced SPMs compared with the general BC population, and the risk is extraordinarily small. Although larger cohorts and longer follow-up are needed, these results support the safety of RT in BRCA carriers." @default.
• W3008629622 created "2020-03-06" @default.
• W3008629622 creator A5010780830 @default.
• W3008629622 creator A5022852084 @default.
• W3008629622 creator A5030577128 @default.
• W3008629622 creator A5031095254 @default.
• W3008629622 creator A5031160818 @default.
• W3008629622 creator A5031247002 @default.
• W3008629622 creator A5054732445 @default.
• W3008629622 creator A5056048404 @default.
• W3008629622 creator A5061830380 @default.
• W3008629622 creator A5061973631 @default.
• W3008629622 creator A5064784116 @default.
• W3008629622 creator A5073971357 @default.
• W3008629622 creator A5078948310 @default.
• W3008629622 creator A5080768897 @default.
• W3008629622 creator A5083828837 @default.
• W3008629622 date "2020-06-01" @default.
• W3008629622 modified "2023-10-04" @default.
• W3008629622 title "Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer" @default.
• W3008629622 cites W1595287457 @default.
• W3008629622 cites W1755658704 @default.
• W3008629622 cites W1828494712 @default.
• W3008629622 cites W1881645183 @default.
• W3008629622 cites W1929113708 @default.
• W3008629622 cites W1963572715 @default.
• W3008629622 cites W1978537515 @default.
• W3008629622 cites W1983598709 @default.
• W3008629622 cites W1984266465 @default.
• W3008629622 cites W1984431444 @default.
• W3008629622 cites W1994960278 @default.
• W3008629622 cites W2024160646 @default.
• W3008629622 cites W2040593396 @default.
• W3008629622 cites W2058064521 @default.
• W3008629622 cites W2069008918 @default.
• W3008629622 cites W2073129224 @default.
• W3008629622 cites W2076514228 @default.
• W3008629622 cites W2077236487 @default.
• W3008629622 cites W2082740117 @default.
• W3008629622 cites W2100025800 @default.
• W3008629622 cites W2116389010 @default.
• W3008629622 cites W2129825983 @default.
• W3008629622 cites W2131209256 @default.
• W3008629622 cites W2133180395 @default.
• W3008629622 cites W2143561393 @default.
• W3008629622 cites W2162039240 @default.
• W3008629622 cites W2330837897 @default.
• W3008629622 cites W2520230173 @default.
• W3008629622 cites W2589066458 @default.
• W3008629622 cites W2598117381 @default.
• W3008629622 cites W2616027747 @default.
• W3008629622 cites W2627871710 @default.
• W3008629622 cites W2735713677 @default.
• W3008629622 cites W2800585982 @default.
• W3008629622 cites W2900768187 @default.
• W3008629622 cites W2997437742 @default.
• W3008629622 cites W4234375295 @default.
• W3008629622 cites W71651760 @default.
• W3008629622 doi "https://doi.org/10.1016/j.ijrobp.2020.02.020" @default.
• W3008629622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32084523" @default.
• W3008629622 hasPublicationYear "2020" @default.
• W3008629622 type Work @default.
• W3008629622 sameAs 3008629622 @default.
• W3008629622 citedByCount "16" @default.
• W3008629622 countsByYear W30086296222020 @default.
• W3008629622 countsByYear W30086296222021 @default.
• W3008629622 countsByYear W30086296222022 @default.
• W3008629622 countsByYear W30086296222023 @default.
• W3008629622 crossrefType "journal-article" @default.
• W3008629622 hasAuthorship W3008629622A5010780830 @default.
• W3008629622 hasAuthorship W3008629622A5022852084 @default.
• W3008629622 hasAuthorship W3008629622A5030577128 @default.
• W3008629622 hasAuthorship W3008629622A5031095254 @default.
• W3008629622 hasAuthorship W3008629622A5031160818 @default.
• W3008629622 hasAuthorship W3008629622A5031247002 @default.
• W3008629622 hasAuthorship W3008629622A5054732445 @default.
• W3008629622 hasAuthorship W3008629622A5056048404 @default.
• W3008629622 hasAuthorship W3008629622A5061830380 @default.
• W3008629622 hasAuthorship W3008629622A5061973631 @default.
• W3008629622 hasAuthorship W3008629622A5064784116 @default.
• W3008629622 hasAuthorship W3008629622A5073971357 @default.
• W3008629622 hasAuthorship W3008629622A5078948310 @default.
• W3008629622 hasAuthorship W3008629622A5080768897 @default.
• W3008629622 hasAuthorship W3008629622A5083828837 @default.
• W3008629622 hasConcept C120665830 @default.
• W3008629622 hasConcept C121332964 @default.
• W3008629622 hasConcept C121608353 @default.
• W3008629622 hasConcept C126322002 @default.
• W3008629622 hasConcept C126838900 @default.
• W3008629622 hasConcept C141071460 @default.
• W3008629622 hasConcept C143998085 @default.
• W3008629622 hasConcept C2779399171 @default.
• W3008629622 hasConcept C2780194787 @default.
• W3008629622 hasConcept C2908647359 @default.
• W3008629622 hasConcept C509974204 @default.
• W3008629622 hasConcept C530470458 @default.
• W3008629622 hasConcept C61511704 @default.
• W3008629622 hasConcept C71924100 @default.

• next